This Biopharma Giant May Have Just Found Its Ticket To Riches In the COVID-19 Market

This Biopharma Giant May Have Just Found Its Ticket To Riches In the COVID-19 Market

Source: 
Motley Fool
snippet: 

Specifically, Merck has been collaborating with Ridgeback Biotherapeutics on a clinical development program for molnupiravir, an oral antiviral medication. Management is hoping this partnership will finally pay off in the form of an outpatient COVID-19 treatment.